Coherus BioSciences company info

What does Coherus BioSciences do?
Coherus BioSciences (NASDAQ:CHRS) specializes in developing and commercializing biosimilar therapies, aiming to increase access to important medications for patients worldwide. The company operates in a highly competitive and regulated biopharmaceutical space, focusing on oncology and immuno-oncology products among other therapeutic areas. Coherus BioSciences' project pipeline is designed to challenge the status quo in medicine, with the objective of providing more affordable and accessible treatment options. Through strategic collaborations and in-house development, the company works tirelessly to bring transformative medications to market, reflecting its commitment to improving patient care and outcomes.
Coherus BioSciences company media
Company Snapshot

Is Coherus BioSciences a public or private company?


How many people does Coherus BioSciences employ?


What sector is Coherus BioSciences in?

pie chart
Health Care

Where is the head office for Coherus BioSciences?

location pin
Head Office
Redwood City, United States

What year was Coherus BioSciences founded?

founded flag
Year Founded
What does Coherus BioSciences specialise in?
/Biosimilar Development /Pharmaceutical Manufacturing /Clinical Trials /Immunology Treatments /Oncology Treatments /Global Distribution

What are the products and/or services of Coherus BioSciences?

Overview of Coherus BioSciences offerings
UDENYCA, a biosimilar to Neulasta, helps patients reduce the risk of infection following chemotherapy by stimulating white blood cell growth.
CHS-1420, a Humira biosimilar, aimed at treating autoimmune diseases including rheumatoid arthritis.
Yusimry, a biosimilar to vascular endothelial growth factor blocker Avastin, designed to treat various forms of cancer.
A portfolio of immuno-oncology biosimilars aimed at providing more accessible treatments for cancer patients.

Who is in the executive team of Coherus BioSciences?

Coherus BioSciences leadership team
  • Mr. Dennis M. Lanfear
    Mr. Dennis M. Lanfear
    Chairman, President & CEO
  • Mr. Bryan J. McMichael
    Mr. Bryan J. McMichael
    Interim CFO, Principal Financial and Accounting Officer, SVP-Accounting & Corporate Controller
  • Mr. Richard L. Hameister
    Mr. Richard L. Hameister
    Chief Technical Officer
  • Ms. Jami  Taylor
    Ms. Jami Taylor
    Vice President of Investor Relations
  • Cheston  Turbyfill
    Cheston Turbyfill
    Vice President of Communications
  • Mr. Scott  Saywell
    Mr. Scott Saywell
    Executive Vice President of Corporate Development
  • Ms. Rebecca  Sunshine
    Ms. Rebecca Sunshine
    Chief Human Resources Officer
  • Mr. Michael  Chen
    Mr. Michael Chen
    Senior Vice President of Commercial Analytics & Trade